Ground-breaking heart research to be presented at ESC Congress

Supplementation with Pharma Nord's Bio-Quinone Active Q10 has been the subject of two recent ground-breaking controlled clinical studies, called Q-SYMBIO and KiSel-10.

The studies relate to the treatment and prevention of cardiovascular disease respectively.

A. L. Mortensen will present the results of the Q-SYMBIO study at the European Society of Cardiology Congress on the 31st August 2015.

Breaking new ground
In the Q-SYMBIO study, more than 400 patients with chronic heart failure received a placebo or 3 x 100mg coenzyme Q10 capsules (Bio-Quinone Active Q10) per day for two years. Supplementation with coenzyme Q10 was shown to reduce the risk of cardiac related mortality by 43 per cent.

Q-SYMBIO study

A focus on bio-availability
The importance of coenzyme Q10 bio-availability cannot be over-emphasised. That is, the ability of the substance to be effectively absorbed and therefore used by the body. To be effective for heart function, the supplement must have the ability to raise blood coenzyme Q10 levels to at least 3mcg/ml.

Pharma Nord's Bio-Quinone Active Q10 was used in the Q-SYMBIO study due to its superior bio-availability. It is the official reference product of the International Coenzyme Q10 Association.

August 2015